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Abstract
Background: Elevated lipid profiles and impaired glucose homeostasis are risk factors for several cardiovascular
diseases (CVDs), which, subsequently, represent a leading cause of early mortality, worldwide. The aim of the
current study was to conduct a systematic review and meta-analysis of the effect of apple cider vinegar (ACV) on
lipid profiles and glycemic parameters in adults.
Methods: A systematic search was conducted in electronic databases, including Medline, Scopus, Cochrane Library,
and Web of Knowledge, from database inception to January 2020. All clinical trials which investigated the effect of
ACV on lipid profiles and glycemic indicators were included. Studies were excluded if ACV was used in combination
with other interventions or when the duration of intervention was < 2 weeks. To account for between-study
heterogeneity, we performed meta-analysis using a random-effects model.
Results: Overall, nine studies, including 10 study arms, were included in this meta-analysis. We found that ACV
consumption significantly decreased serum total cholesterol (− 6.06 mg/dL; 95% CI: − 10.95, − 1.17; I2: 39%), fasting
plasma glucose (− 7.97 mg/dL; 95% CI: − 13.74, − 2.21; I2: 75%), and HbA1C concentrations (− 0.50; 95% CI: − 0.90, −
0.09; I2: 91%). No significant effect of ACV consumption was found on serum LDL-C, HDL-C, fasting insulin
concentrations, or HOMA-IR. The stratified analysis revealed a significant reduction of serum TC and TG in a
subgroup of patients with type 2 diabetes, those who took ≤15 mL/day of ACV, and those who consumed ACV for
> 8-weeks, respectively. Furthermore, ACV consumption significantly decreased FPG levels in a subgroup of studies
that administered ACV for > 8-weeks. Further, ACV intake appeared to elicit an increase in FPG and HDL-C
concentrations in apparently healthy participants.
Conclusion: We found a significant favorable effect of ACV consumption on FPG and blood lipid levels.
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Background
Cardiovascular diseases (CVDs), collectively, are regarded
as the number one cause of early mortality, worldwide
[30]. According to the World Health Organization
(WHO), approximately 17.7 million deaths were attribut-
able to CVD in 2015, and it is projected to account for
more than 23.6 million by 2030 [2]. Indeed, given the high
economic costs of CVDs on healthcare systems, especially
in developing countries, prevention and management of
CVDs is of high priority.
Dyslipidemia, in particular hypercholesterolemia, and
hyperglycemia are regarded as the most important con-
tributors to CVD events [24, 25]. Lifestyle modifications
(dietary changes and physical activity), along with
pharmacological interventions, such as statins, fibrates,
and insulin sensitizers, are routinely used to manage
these metabolic disorders [1, 14, 19, 26]. However, low
adherence to lifestyle recommendations and reported
adverse reactions of synthetic agents [38, 41] highlights
the necessity of discerning novel and efficacious ap-
proaches. In this line, the benefical effect of nutraceutics
and fuctional foods on human health have been well-
documented [8, 36]. In contemporary research and prac-
tice, plants and their derivatives have attracted a lot of
interest for their beneficial effects in controlling lipid
profile and glycemic status [5, 15, 37]. Indeed, one of the
most popular plant derivatives in this regard is vinegar.
Apple cider vinegar (ACV) is one of the three most
common types of vinegar, produced by fermenting ap-
ples [3]. This acidic solution is consumed throughout
the world as a flavoring and preservative agent in foods
[22]. ACV contains a variety of flavonoids, such as gallic
acid, catechin, caffeic acid, and ferulic acid [11, 31]. Ani-
mal experiments have reported that ACV has a variety
of pharmacological functions, including anti-oxidant,
anti-inflammatory, anti-diabetic, anti-hypertensive, and
anti-hyperlipidemic properties [7, 18, 32, 39]. The effects
of ACV on serum lipid parameters and glycemic
markers have been investigated in several randomized
clinical trials [4, 12, 16, 22, 23, 27, 33]; however, the re-
sults are equivocal. Indeed, some investigations have re-
ported beneficial effects following ACV consumption on
the aforementioned parameters [16, 22, 23, 27], although
others failed to detect any effects [4, 12, 33]. It is con-
ceivable that such contradictory findings might be due
to the differences in study design and/or characteristics
of participants (age, sex, clinical condition).
To the best of our knowledge, there has been no sys-
tematic compilation of the previously reported effects of
ACV on lipid profiles and glycemic status. Therefore, in
the current study, we performed a systematic review and
meta-analysis of all published clinical trials to provide a
more precise estimation of the effects of ACV on serum
lipid parameters and glycemic markers in adults.
Methods
The present systematic review and meta-analysis was
planned, conducted, and reported according to the
guidelines of the 2009 Preferred Reporting Items for Sys-
tematic Reviews and Meta- Analysis (PRISMA) state-
ment [29].
Search strategy
A comprehensive literature search was performed to
identify and appraise investigations that had assessed the
effects of ACV supplementation on lipid profiles and
glycemic parameters. Electronic databases, including
Medline, Scopus, Cochrane Library, and Web of Know-
ledge, were searched from database inception to January
2020. The relevant keywords were used in combination
with the Medical Subject Heading (MeSH) terms, search
tag, and boolean operators (AND, OR, NOT) (Supple-
mental Table 1). The search keywords were seldom
based on vinegar and related phrases to minimize the
chance of missing studies which reported lipids or gly-
cemic related markers as secondary outcomes. Addition-
ally, the reference lists of related review articles and the
retrieved studies were also hand-searched to detect eli-
gible trials that might have been missed.
Study selection
After excluding duplicate studies, two authors (AH and
MP) independently reviewed articles based on titles,
abstracts, or full-texts to identify relevant studies. Even-
tually, original studies were included in the present
meta-analysis if they: 1) were randomized clinical trials;
2) administered ACV as the intervention; 3) enrolled
adult participants (aged ≥18 years); 4) reported lipid and
glycemic parameters as the outcomes of interest. Studies
that met the following criteria were excluded: 1) ACV
was used in combination with other interventions; 2)
studies with an intervention duration of fewer than 2
weeks; 3) studies that did not report relevant effect sizes.
Table 1 shows the PICOS (participants, intervention/ex-
posure, comparisons, outcomes, and study design) cri-
teria which was used to define the research question.
Table 1 PICO (participants, intervention/exposure, comparison,




Intervention Apple cider vinegar
supplementation
Comparison Any comparator/control that incorporated
a nonintervention group
Outcomes lipid profile levels and glycemic indices
Setting Randomized controlled trials
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Data extraction and risk of bias assessment
The main information from eligible studies were ex-
tracted by two researchers independently and the follow-
ing data were abstracted: first author’s last name, years
of publication, study location, sample size, participant’s
health condition, mean age of subjects, design and dur-
ation of intervention, comparison groups, type of inter-
vention, and main outcome. Any disagreement was
settled by face-to-face discussion. Furthermore, in in-
stances of unclear information in included studies, clari-
fication was soughtby emailing the relevant studies’
corresponding authors.
The Cochrane Risk of Bias Tool was applied to assess
potential risks of bias in included RCTs [17]. This scale
is based on several items to assess the adequacy of ran-
dom sequence generation, allocation concealment, blind-
ing as well as detection of incomplete outcome data,
selective outcome reporting, and other potential sources
of bias. Based on recommendations of the Cochrane
Handbook, judgment of each item appears by “Low”,
“High”, and “Unclear” risk of bias.
Statistical analysis
All statistical analyses were conducted using the
Cochrane Program Review Manager Version 5.3 (The
Cochrane Collaboration, 2011, The Nordic Cochrane
Centre, Copenhagen) and STATA version 11 software.
To estimate the overall effect size, the mean differences
(MD) and standard deviations (SDs) of all outcomes of
interest, including fasting plasma glucose (FPG), fasting
insulin, HbA1C, homeostasis model assessment of insu-
lin resistance (HOMA-IR), triacylglycerol (TG), total
cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), and high-density protein cholesterol (HDL-C),
were collected. Net changes in these variables in inter-
vention and control groups were computed by the sub-
traction of the post-measurement data from pre-
intervention values if they were not already available in
the original study. As SD of mean change was provided
in only 2 studies [4, 22], we calculated missing SDs of
change for other studies according to the following for-
mula: [SD = square root [(SD pre-treatment)2 + (SD
post-treatment)2 - (2 r × SD pre-treatment × SD post-
treatment)] [17]; where the correlation coefficient (r)
was examined using the following equation: [r = (SD2Base-
line + SD
2
Final-SDChange) / (2× SD Baseline ×SD Final)] [17],
in which required data were obtained from the study of
Bashiri et al. [4]. Based on this, r for TG was considered
as 0.73, for TC as 0.76, for LDL-C as 0.68, and for HDL-
C as 0.66. The corresponding r for FPG, HbA1C,
HOMA-IR and fasting insulin was assumed to be 0.66
for all [17]. To account for probable between-study het-
erogeneity, we applied a random-effects model in our
analyses to estimate the overall effect size [10]. Inter-
study heterogeneity was assessed by Cochran’s Q and I2
statistics, where P < 0.10 or I2 > 50% was regarded as
possessing potential statistical heterogeneity (J. Higgins
& Green). The source of heterogeneity was then ex-
plored through subgroup analysis. Effect sizes were pre-
sented as weighted mean differences with 95%
confidence intervals (CI). The sensitivity analysis was ap-
plied to assess the influence of individual studies on the
overall findings. Egger’s regression asymmetry test and
Begg’s rank-correlation test were performed to explore
potential publication bias [13, 40]. A random-effects
meta-regression was conducted to identify the potential
impact of putative moderators, including baseline mea-
sures, amount, and duration of apple vinegar administra-
tion on estimated net changes of outcome [6]. P-values
< 0.05 were, a priori, considered as statistically
significant.
Results
The study selection process, including the number and
the reason for excluded studies are illustrated in Fig. 1.
In brief, the primary electronic search yielded 4643 un-
duplicated records, where 4628 articles were removed
following title/abstract screening, and thus, 15 studies
were selected for further assessment. Six studies were
excluded due to duplicated data (n = 2), duration of
intervention < 1 week (n = 1), and the use of non-apple
vinegar (n = 3). One selected study [23] had used 2 dif-
ferent doses of ACV; therefore, it was considered as 2
interdependent active arms. Therefore, 9 studies, includ-
ing 10 study arms, were included in the final meta-
analysis.
Study characteristics
The main characteristics of included clinical trials are
provided in Table 2. Nine studies [4, 12, 16, 20, 22, 23,
27, 28, 33], comprising 686 total participants, with a
mean age of 49.5 y, met the eligibility criteria and were
selected for qualitative and quantitative analysis. These
studies were published between 2008 and 2019, and had
been conducted in Iran [4, 12, 22, 27, 28], USA [33],
Japan [23], Pakistan [20], and Tunisia [16], respectively.
Aside from one study [16], which did not report the gen-
der of participants, all included studies had recruited
both genders. Participants’ clinical conditions were dif-
ferent across the included studies; where five trials had
enrolled diabetic patients [12, 16, 20, 27, 28], 2 studies
had included obese and/or overweight participants [22,
23], one study had recruited type 2 diabetic patients with
dyslipidemia [4], and one study did not report the condi-
tion of subjects [33]. All trials were of parallel design
and the duration of intervention ranged between 30 and
90 days. The dose of ACV varied from 15 to 770 mL/
day. Participants in control groups were prescribed
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water/beverage [16, 20, 23, 27, 28, 33] or a restricted-
calorie diet [22]. Two studies [4, 12] had no administra-
tion in control groups.
Risk of bias assessment
The author’s judgment on each criterion of the risk of
bias assessment is presented in Table 3. In summary, 8
trials [4, 12, 16, 20, 22, 23, 28, 33] were randomized,
however, only 3 studies [20, 22, 33] had provided enough
information regarding allocation concealment. Three
studies [20, 23, 33] were blinded. Seven studies [4, 12,
20, 22, 23, 28, 33] had low attrition bias and/or de-
scribed the reason of participants’ withdrawal. Three tri-
als had reported the controlling of other factors that
may influence outcomes [4, 20, 22].
Meta-analysis
The effect of ACV administration on lipid profile
Findings from 8 studies, with 9 effect sizes, revealed that
ACV consumption significantly decreased serum TC
concentrations (− 6.06 mg/dL; 95% CI: − 10.95, − 1.17,
P = 0.02; I2: 39%). In addition, a trend toward a signifi-
cant reduction in serum TG levels was also seen follow-
ing ACV consumption (− 33.66 mg/dL; 95% CI: − 67.87,
0.54, P = 0.05; I2: 95%). No significant effect of ACV con-
sumption on serum LDL-C (− 2.12 mg/dL; 95% CI: −
10.09, 5.85, P = 0.60; I2: 81%) and HDL-C concentrations
was found after ACV consumption (0.92 mg/dL; 95% CI:
− 0.42, 2.27, P = 0.18; I2: 22%) (Fig. 2).
To discern the source of heterogeneity, we performed
subgroup analyses based on participant’s condition, dose
of ACV consumption, and the duration of intervention.
In these analyses, we found a notable decrease in both
TG and TC concentrations in studies conducted on type
2 diabetic patients (TG: − 22.46 mg/dL; 95% CI: − 40.27,
− 4.65; I2: 0%; TC: − 11.51 mg/dL; 95% CI: − 18.16, −
4.86; I2: 0%), as well as in studies with an ACV dose of
≤15mL/day (TG: − 21.91 mg/dL; 95% CI: − 35.23, − 8.60;
I2: 0%; TC: − 10.22 mg/dL; 95% CI: − 16.46, − 3.98; I2:
0%) and studies with > 8-weeks of intervention (TG: −
48.22 mg/dL; 95% CI: − 92.83, − 3.60; I2: 96%; TC: − 7.61
mg/dL; 95% CI: − 14.29, − 0.94; I2: 49%). However, no
significant reduction in these variables was found in
studies conducted on non-diabetics, studies that admin-
istered > 15mL/day, and those with a duration of inter-
vention of ≤8-weeks. In addition, a significant increase
in serum HDL-C levels was observed in studies that re-
cruited non-diabetics (HDL-C: 1.73 mg/dL; 95% CI: 0.28,
3.18; I2: 0%) (Table 4).
The effect of ACV administration on glycemic profile
Pooled effect size from 6 studies, with 7 effect sizes, re-
vealed a significant reduction in FPG (− 7.97mg/dL; 95%
CI: − 13.74, − 2.21, P = 0.007; I2: 75%) after ACV
Fig. 1 Flow chart of the process of the study selection
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consumption. The same findings were obtained for
HbA1C, when we combined 6 effect sizes from 5 studies
(− 0.50mg/dL; 95% CI: − 0.90, − 0.09, P = 0.02; I2: 91%).
No significant effect of ACV consumption was found on
serum insulin levels (− 0.85mg/dL; 95% CI: − 2.73, 1.02,
P = 0.37; I2: 0%) and HOMA-IR (− 0.31mg/dL; 95% CI: −
0.80, 0.17, P = 0.21; I2: 18%) (Fig. 3).
Subgroup analysis revealed a significant reduction in
FPG in studies recruited non-diabetics (− 3.53mg/dL; 95%
CI: − 6.70, − 0.37; I2: 0%). Such an effect was not observed
in studies that enrolled diabetic patients (− 16.28mg/dL;
95% CI: − 33.02, − 0.47; I2: 83%). Furthermore, when stud-
ies were stratified based on duration of intervention, the
lowering effect of ACV on FPG was found in studies with
an intervention of > 8-weeks follow-up (− 3.78mg/dL;
95% CI: − 6.90, − 0.66; I2: 0%). No significant effect of
ACV consumption on FPG was seen in studies with a low
or high dose of ACV. When we excluded the study of
Mohammadpourhodki et al. (36), between-study hetero-
geneity became non-significant (− 3.09mg/dL; 95% CI: −
5.83, − 0.35; I2:23%). In addition, the lowering effect of
ACV on HbA1C was non-significant in all subgroups
(Table 4). Due to the low number of trials in each sub-
group, stratified analysis was not conducted for serum in-
sulin levels and HOMA-IR.
Meta-regression
Findings from the meta-regression indicated an inverse
association between change in FPG and HbA1C levels
and baseline levels of these indicators (FPG: coefficient:
-0.24; 95% CI: − 0.40, − 0.07; HbA1C: coefficient: -0.21;
95% CI: − 0.39, − 0.03). However, the effect of ACV in-
take on FPG and HbA1C was independent of the dose
of ACV and duration of the study. Furthermore, no as-
sociation was observed between change in other out-
comes of interest following ACV intake and baseline
measures, the dose of intervention, and duration of
follow-up (Supplemental Table 2).
Sensitivity analysis
Sensitivity analysis was performed by excluding individ-
ual studies from the meta-analysis. We found that our
findings about serum TG was influenced by 3 studies,
and when we removed each of these studies from the
analysis, the findings did change [excluding Panetta et al.
[33] WMD: − 39.38 mg/dL; 95% CI: − 73.18, − 5.59; ex-
cluding Mahmoodi et al. [27] WMD: − 39.46 mg/dL;
95% CI: − 75.37, − 3.55; and excluding Khezri et al. [22]
WMD: − 20.76 mg/dL; 95% CI: − 36.86, − 4.65]. This was
also the case when we removed the study of Bashiri
et al. [4] in our analysis on serum HDL-C levels (WMD:
1.68 mg/dL; 95% CI: 0.44, 2.92); such that serum HDL-C
levels were significantly increased by ACV consumption.
With regards to HbA1C, we found that the study by
Mohammadpourhodki et al. [28] had a significant effect
on the overall finding; such that after removing that
study from the analysis, no significant effect on HbA1C
was seen following ACV consumption (− 0.04%; 95% CI
-0.18, 0.10).
In addition, when we excluded studies with a high-risk
of bias [12, 16, 27, 28], no alterations in findings oc-
curred. Except for the findings of HbA1C, which became
non-significant (− 0.03%; 95% CI: − 0.16, 0.10) (Supple-
mental Figure 1).
Publication bias
Funnel plot showed a slight to moderate asymmetry
in some variables (Supplemental Figure 2). Based on
Egger’s regression asymmetry and Begg’s rank correl-
ation test, we found no evidence of publication bias
in studies on TG, TC, HDL-C, and HbA1C. However,
a significant asymmetry was found in studies on
serum LDL-C (P = 0.005) and FPG (P = 0.04)











Bashiri et al. [4] L U H L L L
Halima et al. [16] L U U U L U
Kondo et al. [23] L U L L L U
Mahmoodi et al. [27] U H U U L U
Panetta et al. [33] L L L L L U
Khezri et al. (2018) [22] L L H L L L
Ebrahimi-Mamaghani et al. [12] L U H L L U
Mohammadpourhodki et al.
(2019) [28]
L U H L L U
Kausar et al. (2019) [20] L L L L L L
H high risk of bias, L low risk of bias, U unclear or unrevealed risk of bias. Criteria defined for risk of bias assessment are according to the Cochrane guidelines
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Fig. 2 The meta-analysis results of the effect of apple cider vinegar administration on lipids profiles. Kondo et al. study administrated apple cider
vinegar in 2 different dosages which showed as “L” (lower dose) and “H” (higher dose) in figure
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according to Egger’s regression test, although, such
results were not confirmed by Begg’s rank-correlation
test (LDL-C: P = 0.40; FPG: P = 0.17).
Discussion
The present systematic review and meta-analysis sug-
gested that ACV consumption yielded beneficial effects
on serum TC and FPG levels. In addition, a trend to-
ward a significant favorable effect was also observed in
serum TG concentrations.
Hyperlipidemia and hyperglycemia are common metabolic
disorders that affect many people around the world [34, 36].
In spite of several strategies to manage these abnormalities,
lifestyle modifications are the first line of therapy in these
conditions. Indeed, findings from the present meta-analysis
highlight the application of ACV, as a dietary agent, may be
helpful in controlling these metabolic abnormalities [9].
The present study showed that ACV consumption im-
proved serum levels of FPG. With regard to HbA1C,
despite the significant overall effect of ACV, we found
Fig. 3 The meta-analysis results of the effect of apple cider vinegar administration on glycemic related factors. Kondo et al. study administrated
apple cider vinegar in 2 different dosages which showed as “L” (lower dose) and “H” (higher dose) in figure
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that the exclusion of one study resulted in a non-
significant finding, indicating that the overall findings
were study-dependent. The mechanism of the ACV ef-
fect on lipid profiles and glycemic related markers has
not been well defined; however, empirical studies have
suggested several potential mechanisms. Indeed, ACV
can improve glycemic status by delaying gastric empty-
ing, enhancing cellular glucose utilization and lipolysis,
suppressing hepatic glucose production and lipogenesis,
and facilitating insulin secretion [21, 35]. Furthermore,
in our study, the beneficial effect of ACV on FPG levels
was more pronounced when the duration of studies











TG Participants condition Type 2 diabetes 5 −22.46 (−40.27, −4.65) 0% 0.001
Other condition 4 −40.86 (−93.61, 11.88) 97%
Amount of apple vinegar > 15mL/day 5 − 47.59 (−101.58, 6.67) 96% < 0.001
≤ 15mL/day 4 −21.91 (−35.23, −8.60) 0%
Duration > 8 weeks 4 −48.22 (−92.83, − 3.60) 96% < 0.001
≤ 8 weeks 5 −9.51 (− 33.63, 14.60) 32%
TC Participants condition Type 2 diabetes 5 −11.51 (− 18.16, −4.86) 0% 0.01
Other condition 4 −3.21 (−8.81, 2.40) 47%
Amount of apple vinegar > 15mL/day 5 −4.00 (−10.19, 2.19) 46% 0.03
≤ 15mL/day 4 −10.22 (− 16.46, −3.98) 0%
Duration > 8 weeks 4 −7.61 (−14.29, −0.94) 49% 0.75
≤ 8 weeks 5 −5.71 (−14.33, 2.92) 49%
LDL-C Participants condition Type 2 diabetes 5 −5.39 (− 14.31, 3.53) 48% 0.002
Other condition 4 1.62 (−9.85, 5.85) 87%
Amount of apple vinegar > 15mL/day 5 −0.59 (−11.73, 10.55) 85% 0.003
≤ 15mL/day 4 −4.34 (−12.51, 3.84) 38%
Duration > 8 weeks 4 −1.41 (− 16.36, 13.55) 90% 0.02
≤ 8 weeks 5 −1.66 (−8.83, 5.51) 38%
HDL-C Participants condition Type 2 diabetes 5 0.21 (−2.17, 2.60) 34% 0.10
Other condition 4 1.73 (0.28, 3.18) 0%
Amount of apple vinegar > 15mL/day 5 0.39 (−1.78, 2.57) 56% 0.49
≤ 15mL/day 4 1.61 (−0.52, 3.75) 0%
Duration > 8 weeks 4 1.62 (− 0.07, 3.30) 0% 0.32
≤ 8 weeks 5 0.52 (−1.75, 2.79) 48%
FPG Participants condition Type 2 diabetes 5 −16.28 (−33.02, 0.47) 83% 0.69
Other condition 2 −3.53 (−6.70, −0.37) 0%
Amount of apple vinegar > 15mL/day 3 −16.12 (−41.31, 9.07) 87% 0.15
≤ 15mL/day 4 −4.10 (−8.98, 0.76) 52%
Duration > 8 weeks 3 −3.78 (− 6.90, −0.66) 0% 0.55
≤ 8 weeks 4 −17.14 (−38.15, 3.86) 86%
HbA1C Participants condition Type 2 diabetes 3 −0.77 (−1.56, 0.02) 88% 0.001
Other condition 3 −0.07 (− 0.32, 0.18) 0%
Amount of apple vinegar > 15mL/day 3 −0.60 (−1.54, 0.33) 92% 0.13
≤ 15mL/day 3 −0.24 (− 0.51, 0.03) 10%
Duration > 8 weeks 3 −0.72 (−1.58, 0.15) 90% 0.01
≤ 8 weeks 3 −0.14 (− 0.43, 0.15) 23%
The effect size was obtained from random effect model. Abbreviations: TG triacylglycerol, TC total-cholesterol, LDL-C Low-density lipoprotein cholesterol, HDL-C
High-density lipoprotein cholesterol, FPG Fasting Plasma Glucose
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lasted > 8 weeks. Subgroup analysis revealed that the FPG
lowering effect of ACV was not significant in non-diabetic
patients. On the other hand, the meta-regression results
indicated a negative association between changes in both
HbA1C and FPG levels, and their baseline measures.
These findings suggest that higher baseline values of
FPG and HbA1C might contribute to a greater reduc-
tion in these markers following ACV intake.
This study revealed that ACV consumption might re-
duce serum TC concentrations; where the effect of ACV
on lipid profiles might be attributed to its stimulation of
acid bile excretion, increasing lipolysis and decreasing
lipogenesis [21, 35]. Subgroup analysis indicated a
greater beneficial effect on both TC and TG levels
among type 2 diabetics patients. In addition, the effect
on TG and TC was more notable when interventions
lasted > 8 weeks. The results from subgroup analysis also
showed a greater lowering effect of ACV on TG and TC
levels in doses of ≤15ml/day. Therefore, 15 ml/day
might represent the optimum effective dose of ACV.
However, our findings from meta-regression analysis did
not indicate an association between the dosage of ACV
intake and serum alterations of these parameters. Never-
theless, the null results from meta-regression analysis
might be due to the paucity of data in terms of ACV
doses in published studies. We also found a significant
improvement in HDL-C among non-diabetic partici-
pants. Given that diabetic patients are susceptible to
higher levels of oxidative stress and the reductions of the
expression and/or activity of HDL-C’s anti-oxidative en-
zymes, such as paraoxonase, in these patients, it is rea-
sonable to expect a higher dosage of ACV would be
more effective in these individuals. Therefore, further in-
vestigations would be required to shed light on this issue
in diabetic patients.
ACV appears to be a safe natural supplement with a
functional role in controlling glycemic and lipid profiles.
Only two studies [4, 20] had reported some side effects
(such as stomach burning and ACV intolerance) follow-
ing consumption of this supplement. The present sys-
tematic review and meta-analysis has some limitations
which must be taken into account. The number of in-
cluded studies, in particular in terms of insulin and
HOMA-IR, was relatively low, thereby precluding reli-
able conclusions to be drawn. Between-study heterogen-
eity was high for some outcomes, and although we
endeavoured to find the source of heterogeneity in sub-
group analysis, the heterogeneity remained significant in
some subgroups. Most studies did not control the partic-
ipant’s dietary intake, which might influence study out-
comes. Finally, some trials were potentially high risk of
bias in methodology, especially in blinding. However, ex-
cept for HbA1C, the findings did not change by exclud-
ing studies with a high risk of bias.
Conclusion
Following systematic review and meta-analysis, we found
that ACV consumption might beneficially affect gly-
cemic status and lipid parameters in adults; however,
due to some limitations, the findings should be inter-
preted with caution. Considering that ACV is a safe
food, it could be considered as a functional food and ad-
juvant therapy in the management of metabolic abnor-
malities. However, further studies are needed to clarify
all possible beneficial effects of ACV on glycemic
markers and lipid profiles.
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